Abstract
The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.
Original language | English |
---|---|
Pages (from-to) | 17-24 |
Journal | European Journal of Endocrinology |
Volume | 174 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2016 |
Subject classification (UKÄ)
- Endocrinology and Diabetes